Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development
Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX8743, a potential first-in-class small molecule modulator of MYC condensates, into clinical development.
